Frostbite is the most common cold injury and is thus an ever-present danger to mountaineers. Frostbite has been classified into 4 degrees according to physical signs and subsequent sequelae. First-degree frostbite involves only the epidermis and causes erythema, mild edema, and cold insensitivity for several weeks after the injury. Second-degree frostbite is a full-thickness injury resulting in severe edema and blistering, which leads to a large eschar over several weeks. Sequelae include paresthesias and possible permanent cold insensitivity. Third-degree frostbite involves hemorrhagic blisters; dark discoloration of the skin; severe pain with rewarming; and the development of a thick, gangrenous eschar. Sequelae include deep ulceration and severe cold insensitivity. Fourth-degree frostbite is a full-thickness injury including muscle, tendon, and bone. Amputation is often necessary in third-and fourthdegree frostbite.
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This study was designed to obtain more information about the risk factors of frostbite in mountaineers in the hopes of developing successful prevention techniques. A total of 637 mountaineers completed a questionnaire that was then used in this cross-sectional descriptive study. The mountaineers were included only if they completed at least 2 ascents per month to summits higher than 3000 m. All the mountaineers reported on personal incidents of frostbite that had occurred in the preceding 2 years. Descriptions of the injuries included body part affected, degree of frostbite, associated altitude, season of injury, appropriateness of equipment, and whether or not a guide was involved in the problematic ascent.
A total of 467 incidents of frostbite occurred in the 637 study participants in the 2 years preceding the survey, thus providing a mean annual incidence of 366 per 1000 mountaineers. There was no significant relationship between age, sex, or level of mountaineering experience and the incidence of frostbite. First-degree frostbite was found in 83% of participants self-reporting frostbite, with 26% involving the hand and 24% involving the foot. Significant risk factors included not having a guide (P Ͻ .001), using inappropriate equipment (leading to 45% of injuries), climbing at lower altitudes, and climbing during the winter months. The incidence of frostbite per 1000 mountaineers was 304 for first-degree frostbite, 42 for second-degree frostbite, 16 for third-degree frostbite, and 5 for fourth-degree frostbite.
The findings of this study may appear to be somewhat intuitive, yet the data reinforce several key points of prevention. Although they were experienced, the mountaineers tended to develop frostbite when they were less prepared for the elements, that is, when there was inadequate equipment, when there was no guide, and when the mountaineers attempted lower and possibly ''less serious'' climbs. In this population, frostbite was less of a concern at higher altitudes, but such altitudes involved the well-planned, well-equipped, summer expeditions. Because hands and feet are the most affected body parts, the importance of good mittens and boots cannot be overstressed. Layering, preparation, and planning should all be taught as methods of prevention, particularly to those who may be attempting casual yet significant ascents to only moderate elevations. 
Cooling Methods Used in the Treatment of Exertional Heat Illness
Heatstroke continues to be a common cause of preventable mortality in the United States. Cell damage results from uncoupling of oxidative phosphorylation, leading to an increase in sodium-potassium adenosine triphosphate activity, energy depletion, increased heat production, and ultimately end-organ damage. Two separate forms of the condition exist, environmental (classic) and exertional, though the forms are indistinguishable clinically. This article reviews the available data in an attempt to establish an evidence-based treatment guideline for heatstroke. The author used Medline, Premedline, Embase, SPORTDiscus, and Evidence Based Medicine as search engines and found 17 qualifying articles to include in the analysis. Studies qualified for review if they contained original data on cooling rates or times in either patients with heat injuries or normal subjects under experimental conditions. The author makes 3 important conclusions from his analysis.
First, the cooling method of choice should be whole-body ice-water immersion, which has been shown to result in a cooling rate of up to 0.20ЊC·min
Ϫ1
. Practically speaking, this maneuver is not always feasible and may be inappropriate for unconscious patients or too painful for those with intact faculties. For these patients, lowering the body temperature with cold-water sprays and external fans (body cooling unit) provides an alternative approach and expedites one of the body's natural methods for reducing core temperature. Despite a theoretical concern that cold-water immersion may induce peripheral vasoconstriction inhibiting the cooling rate, a recent study included in the analysis found that cooling rates were fastest when the coldest water possible was used. The rate of cooling is relevant because the main predictor of outcome was duration and degree of hyperthermia.
Second, there is no evidence to support the use of dantrolene for heatstroke. Interestingly, dantrolene inhibits calcium efflux from the sarcoplasmic reticulum of skeletal muscle, which ultimately decreases muscular contraction. Although this mechanism of action is helpful in the treatment of conditions associated with muscular rigidity or hypertonicity, such as neuroleptic malignant syndrome and malignant hyperthermia, it does not appear to work for heatstroke. This conclusion is based on 2 prospective randomized controlled trials that compared dantrolene with placebo. The first study contained 20 patients with classic heatstroke, and though there was a significant difference in mean cooling time in the treatment group, there was no overall difference in mortality. This study, however, had several limitations, including poorly defined inclusion criteria; small numbers; failure to define randomization; inadequate powering; and alternating medication doses, which sparked cautious interpretation among the authors. The second study, which had superior methodology, included 52 patients with classic heatstroke and showed no significant difference in cooling time, organ dysfunction, length of hospital stay, or mortality.
Finally, because there has yet to be a study designed to compare cold-water immersion with evaporative cooling methods, more work is needed in this field. In addition, there is very little evidence supporting the use of combined evaporative cooling methods. The paucity of studies, small study populations, faulty study designs, varying study endpoints, use of experimentally induced hyperthermia, and conflicting conclusions make what is available largely unhelpful. Miscellaneous methods such as cold-water peritoneal, gastric, and bladder lavage and the downdraft of a helicopter propeller have all been investigated, but there is no good evidence to support their use. Currently, heatstroke should be managed by removal of the patient from the environment; meticulous attention to airway, breathing, and circulation; resuscitation if necessary; and whole-body cold-water immersion. However, if immersion is not possible or is dangerous, then rapid cooling by evaporative methods, ice bags, placing the hands and feet in cold water, or a combination of these methods should be instituted as soon as possible to facilitate rapid lowering of core body temperature. 
CRITICAL CARE MEDICINE

Resuscitation From Experimental Heatstroke by Hyperbaric Oxygen Therapy
Heatstroke is a clinical diagnosis made from the presence of hyperthermia; shock; and neurologic abnormalities such as delirium, seizures, or coma. Cerebral ischemia and hypoxia are present, as are levels of multiple organ failure. Endotoxins and cytokines such as tumor necrosis factor (TNF) and interleukins are often present, thus providing similarities between heatstroke and sepsis. Hyperbaric oxygen (HBO) therapy has been shown to decrease brain ischemia and levels of TNF in experimental models and was used in this study as a noninvasive means for resuscitation in experimental heatstroke.
This animal model categorized anesthetized rats into the following groups after the induction of experimental environmental heatstroke (by exposing animals to an ambient temperature of 43ЊC): 1) no resuscitation except removal from heat exposure, 2) HBO for 1 hour, 3) HBO for 2 hours, 4) cyclic HBO for 1 hour of treatment with one 5-minute break, 5) hyperbaric air for 1 hour, 6) normobaric hyperoxia, or 7) hyperbaric 8% oxygen for 1 hour. Onset of heatstroke was defined as the time that mean arterial pressure began to decrease from baseline. The following parameters were monitored and measured: body temperature, mean arterial pressure, heart rate, arterial blood gases, TNF, and evidence of cortical neuronal damage (evaluated by histochemical staining and analysis of section slides).
Survival times of the rats were best in the group treated with cyclic HBO, followed by rats treated with HBO for 1 and 2 hours. Any treatment with HBO was superior in length of survival time compared with hyperbaric air, normobaric hyperoxia, or hyperbaric 8% oxygen (P Ͻ .05). Although all treatments were somewhat effective in attenuating the physiologic effects of heatstroke such as acidosis, hypotension, and production of TNF, only HBO treatments (1 hour and cyclic) showed a significant attenuation of hypotension, bradycardia, hypoxia, and neuronal cortical damage (P Ͻ .05).
Hyperbaric oxygen is thought to improve survival in this population by decreasing cerebral blood flow and intracranial pressure, thus protecting cortical neurons. In addition, in this study, HBO attenuated systemic acidosis and the production of TNF by improved tissue oxygenation. In this experimental model, HBO, particularly when applied in a cyclic pattern, did improve survival significantly compared with alternative treatments, including regular cooling, hyperbaric air, or plain oxygenation. However, human studies have not been completed, and HBO has not been tested in conjunction with other standardized treatments of heatstroke, including external cooling, invasive cooling, or fluid resuscitation. More importantly, expanding the use of HBO for conditions like heatstroke is problematic due to regional availability as well as the difficulty in managing critically ill patients within a chamber. Sudden exposure to high altitudes may result in acute mountain sickness (AMS), possibly progressing to high-altitude ce-rebral edema. Vascular endothelial growth factor (VEGF) is a protein that increases vascular permeability and can induce cerebral edema in animals. Although expression of VEGF increases with altitude, previous studies have shown no correlation between plasma VEGF levels and AMS. However, concentrations of another protein, soluble fms-like tyrosine kinase receptor-1 (sFlt-1), increase with hypoxia. This protein binds plasma VEGF, thereby reducing the amount available to bind endothelium and increase permeability. These researchers hoped to show that plasma concentrations of sFlt-1 would be lower and that unbound VEGF would be higher in subjects who acquired AMS compared with well subjects on acute exposure to high altitude.
Twenty healthy adult subjects were driven for over 2 hours from their place of residence to Pike's Peak in the Colorado Rocky Mountains, where they stayed overnight. Plasma was collected both at low (between 1370 and 1645 m) and at high (4300 m) altitudes. The plasma was analyzed for VEGF, sFlt-1, and erythropoietin (a marker of altitude stress). Acute mountain sickness was diagnosed by the Environmental Symptoms Questionnaire, the Lake Louise Score, and the presence of headache. Paired Student's t tests were used to analyze lowto high-altitude data.
Of the 20 participants, 9 were diagnosed with AMS. Mean free plasma VEGF concentrations increased almost 10-fold with altitude in both well and AMS groups, but the increase was statistically significant only in the AMS group. Plasma sFlt-1 increased with altitude in both groups but was significantly lower in both low-and high-altitude samples from subjects who developed AMS. Erythropoietin increased similarly at high altitudes in all subjects, indicating a similar altitude stress between the 2 groups. Oxygen saturation was equivalent between AMS subjects and well subjects at high altitude.
This study differed from studies showing no correlation between VEGF and AMS by using a more acute ascent profile, using paired data analysis because each subject was his or her own control, and taking measurements of sFlt-1. Although the researchers' findings are clear and provocative regarding the lesser concentrations of sFlt-1 in AMS subjects, their findings regarding VEGF are more troublesome. Despite the researchers' claim of greater concentrations of VEGF at high altitudes in AMS subjects than in well subjects, the tabulated data show no statistically significant difference between these 2 groups. In fact, the data show a greater difference between high-and low-altitude mean VEGF concentrations in well subjects than in AMS subjects. In making their claims, the researchers appear to be relying on the trend of insignificantly greater levels of VEGF in AMS subjects at high altitude. In contrast to this reliance on trend despite a lack of statistical significance, the statement that VEGF increased at high altitude in the AMS group but not in the well group is made in spite of an evident 10-fold (though not statistically significant) increase in VEGF in the well group. The researchers mention that small sample size may have led to large variation, which may have obscured potential differences between VEGF at low-and high-altitudes in well subjects. Although sFlt-1 levels may potentially predict a subject's susceptibility to AMS, more research is needed to clarify the relationship among AMS, VEGF, and sFlt-1. 
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Spectrum of Disease and Relation to Place of Exposure Among Ill Returning Travelers
Approximately 4 million individuals each year seek health care while traveling or after returning home. Although most travel-related illnesses are self-limited (eg, diarrhea, respiratory infections, skin infections), others are more serious and require higher levels of care. GeoSentinel sites are 30 specialized travel or tropical medicine clinics found on 6 continents and are mostly associated with academic centers. They receive both tertiary and self-referrals, and they input data into a large surveillance database. This database would not include information from small, primary care clinics or information from patients with self-limited illness who did not seek medical attention, but it does include data from a large number of travelers returning from a broad range of destinations throughout the world.
The 30 GeoSentinal sites contributed data from ill returning travelers between 1996 and 2004. The data were used to compile the frequency of occurrence of various disorders from 6 developing regions of the world. Patients were included if their diagnoses were laboratory confirmed or deemed probable (by laboratory exclusion of other diagnoses). The place of exposure was concluded by travel history and by the use of incubation periods and patters of endemicity.
A total of 17 353 patients met inclusion criteria and had exposures from 230 countries. More than half had consulted with physicians before traveling. Sixty-seven percent of all reported illnesses fell into 4 categories: systemic febrile illness, acute diarrhea, chronic diarrhea, and dermatologic illness. Sixty-four percent were seen within 1 month of travel, and 10% were seen more than 6 months after travel. Systemic febrile illness was found disproportionately among patients from subSaharan Africa and Southeast Asia, whereas diarrhea illness was found more after travel to south-central Asia (P Ͻ .01). Overall, malaria was the most common cause of systemic febrile illness; however, dengue caused more febrile illness than did malaria in all geographic regions except sub-Saharan Africa and Central America. Rickettsial infection, especially tickborne spotted fever, occurred more commonly than dengue or typhoid in sub-Saharan Africa. Parasites caused more diarrhea than did bacteria in presenting travelers from all regions except Southeast Asia, where most patients had campylobacter (though giardia was present disproportionately as well). Dermatologic illness was most common in the Caribbean and was often attributed to insect bites, cutaneous larva migrans, allergic reactions, and abscesses.
This study provides an excellent tool for clinicians to use in investigating illness in the returning traveler with moderate to severe illness. Specific travel destinations can now be associated with probabilities of different etiologies of illness. This study shows that though malaria may be common in travelers to sub-Saharan Africa and Central America, dengue may be the most likely cause of fever in travelers to other regions. These findings may be resultant from travelers to many regions having successful prophylaxis against malaria. In travelers to sub-Saharan Africa, rickettsial infection (tick-borne spotted fever) is even more common than typhoid or dengue, which is an important consideration for health care providers if peripheral smears are negative in the febrile traveler. Finally, parasites should be considered the most likely cause of diarrhea in all travelers except those who visited Southeast Asia. This new trend may be secondary to travelers self-treating for bacterial causes of diarrhea. Travelers' diarrhea has long been known as an unpleasant side effect of traveling to certain regions of the world. In addition, chronic (postinfectious) irritable bowel syndrome has been found in between 4% and 31% of patients, which is a significant source of long-term morbidity in many of these individuals. Mechanisms of prevention of travelers' diarrhea have included large doses of bismuth and absorbed antibacterial drugs. Rifaximin has been used as a treatment of acute bacterial diarrhea in Europe, Asia, and Latin America and works by inhibition of bacterial synthesis of RNA. The differentiating mechanism of this medication is that it is minimally absorbed (Ͻ0.4%) and therefore might be superior over absorbed antibacterials, with fewer adverse effects and long-term bacterial resistance.
This randomized, double-blind, placebo-controlled trial was completed with 210 adult students completing course work in Guadalajara, Mexico. Upon their arrival, the students received rifaxamin 200 mg 1, 2, or 3 times daily or placebo 3 times daily for 2 weeks. Subjects were healthy and all received orientation on prevention of travelers' diarrhea, including advice on safe food selection. Each subject documented a daily diary of symptoms and signs. Any loose stools suggestive of diarrhea were collected and examined by a laboratory for gross blood and cultured for organisms. Changes in intestinal coliform flora were noted. Subjects who developed moderate to severe diarrhea received antibiotics and were removed from the remainder of the study.
During the 2-week study period, 54% of subjects taking placebo developed diarrhea, whereas only 15% of the rifaximin subjects developed symptoms (12% in once-daily dosing, 19% in twice-daily dosing, and 13% in thrice-daily dosing). Protection was 72% against mild diarrhea and 77% against diarrhea requiring antibiotics (fever, cramps, nausea/vomiting, blood, or pathogens in stool) (P Ͻ .001 for both). In addition, those in the rifaximin group who did develop travelers' diarrhea requiring antibiotic treatment had less severe diarrhea (P ϭ .02), less pain and cramping (P ϭ .009), and less excess gas (P ϭ .02). The major etiology of diarrhea and mild diarrhea in this population, enterotoxic Escherichia coli, was prevented in the rifaximin study group with a protection rate of 83%. Adverse effects were not increased in the rifaximin group. Rifaximin did not substantially change coliform flora.
This controlled study does show convincing evidence that rifaximin is an effective prophylactic agent against travelers' diarrhea in Mexico, where the etiology is commonly E coli. Additional studies will have to be completed regarding invasive pathogens such as Campylobacter, Shigella, and Salmonella. The authors suggest a regimen of twice-daily rifaximin, which allows the drug to be taken with meals and allows for some remaining protection if a dose is accidentally missed. 
